SCHEMBL15214176

SCHEMBL15214176

Cc1ccc(Cn2c3ncnc4c(ncn4Cc4ccccc4Cl)c-3nc2=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 1/20 0.46
▸ PIK3CD O00329 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ YTHDC1 Q96MU7 1/20 0.41
▸ PDE10A Q9Y233 1/20 0.40
▸ SLC29A1 Q99808 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ PDE1B Q01064 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1312875 0.91 HPGD (0.48) PIK3CDMEN1KMT2AALDH1A1USP2
SCHEMBL12112160 0.89 PDE10A (0.48) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL12112208 0.88 MAPK1 (0.43) PIK3CDMEN1KMT2AALDH1A1USP2
SCHEMBL12112171 0.87 MEN1 (0.47) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL12112188 0.86 PDE10A (0.50) MEN1KMT2AALDH1A1PDE10ASLC29A1
SCHEMBL12112197 0.84 MEN1 (0.44) RXFP1MEN1KMT2AALDH1A1USP2
SCHEMBL12112206 0.84 PDE10A (0.47) PDE10ASLC29A1
SCHEMBL12112183 0.84 PDE10A (0.44) MEN1KMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL12112177 0.84 PDE10A (0.44) LMNAMEN1KMT2ACYP1A2CYP3A4
SCHEMBL12112179 0.84 PDE10A (0.44) MEN1KMT2ACYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9322831-B2 DDX3 as a biomarker for cancer and methods related thereto THE JOHNS HOPKINS UNIVERSITY (US) 2016-04-26 — — US disclosed
US-20130281440-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO THE JOHNS HOPKINS UNIVERSITY 2013-10-24 — — US disclosed
US-8518901-B2 Fused diimidazodiazepine compounds and methods of use and manufacture thereof THE JOHNS HOPKINS UNIVERSITY (US) 2013-08-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281440-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO DDX3X, DDB1, DDX24 RXFP1 4192/4885PIK3CD 2000/4885LMNA 1086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback